Key Points
- Insider Tiffany Eul Davis Inglis sold 8,024 Sera Prognostics shares at an average price of $2.03, totaling $16,288.72. The sale covered tax withholding obligations from vested equity awards and reduced her direct ownership by 8.76% to 83,565 shares.
- Sera Prognostics shares opened at $2.04, near their 50-day and 200-day moving averages, with a market capitalization of approximately $80.5 million. The company recently reported an EPS loss of $0.18, missing estimates, and revenue of just $0.03 million.
- Analyst sentiment remains mixed, with the stock carrying a “Moderate Buy” consensus rating and a $5.50 average price target, while Weiss Ratings downgraded it to “sell (e+).” Institutional investors and hedge funds own 54.64% of the company.
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) insider Tiffany Eul Davis Inglis sold 8,024 shares of the company's stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $2.03, for a total value of $16,288.72. Following the transaction, the insider directly owned 83,565 shares of the company's stock, valued at approximately $169,636.95. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Tiffany Eul Davis Inglis also recently made the following trade(s):
- On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total value of $972.00.
Sera Prognostics Stock Performance
Shares of NASDAQ SERA opened at $2.04 on Wednesday. Sera Prognostics, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $3.95. The firm has a market capitalization of $80.48 million, a PE ratio of -3.04 and a beta of 1.06. The stock's 50-day simple moving average is $2.04 and its 200-day simple moving average is $2.02.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. On average, sell-side analysts forecast that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded shares of Sera Prognostics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $5.50.
Check Out Our Latest Analysis on Sera Prognostics
Hedge Funds Weigh In On Sera Prognostics
Several large investors have recently bought and sold shares of the stock. Arkadios Wealth Advisors purchased a new stake in shares of Sera Prognostics during the first quarter worth approximately $25,000. Segall Bryant & Hamill LLC purchased a new position in Sera Prognostics in the 1st quarter valued at $193,000. Finally, AWM Investment Company Inc. purchased a new position in Sera Prognostics in the 2nd quarter valued at $377,000. Institutional investors and hedge funds own 54.64% of the company's stock.
Sera Prognostics Company Profile
(
Get Free Report)
Sera Prognostics, Inc is a women's health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.
Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
